These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25264600)

  • 1. Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    J Med Chem; 2014 Nov; 57(21):8886-902. PubMed ID: 25264600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.
    Nara H; Sato K; Kaieda A; Oki H; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2016 Dec; 24(23):6149-6165. PubMed ID: 27825552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.
    Ruminski PG; Massa M; Strohbach J; Hanau CE; Schmidt M; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Shieh HS; Caspers N; Collins B; Grapperhaus M; Palmquist KE; Collins J; Baldus JE; Hitchcock J; Kleine HP; Rogers MD; McDonald J; Munie GE; Messing DM; Portolan S; Whiteley LO; Sunyer T; Schnute ME
    J Med Chem; 2016 Jan; 59(1):313-27. PubMed ID: 26653735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
    Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
    Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.
    Nara H; Kaieda A; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    J Med Chem; 2017 Jan; 60(2):608-626. PubMed ID: 27966948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.
    Xie XW; Wan RZ; Liu ZP
    ChemMedChem; 2017 Aug; 12(15):1157-1168. PubMed ID: 28722301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2014 Oct; 22(19):5487-505. PubMed ID: 25192810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Schnute ME; O'Brien PM; Nahra J; Morris M; Howard Roark W; Hanau CE; Ruminski PG; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Patt WC; Shieh HS; Collins B; Pavlovsky AG; Palmquist KE; Aston KW; Hitchcock J; Rogers MD; McDonald J; Johnson AR; Munie GE; Wittwer AJ; Man CF; Settle SL; Nemirovskiy O; Vickery LE; Agawal A; Dyer RD; Sunyer T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):576-80. PubMed ID: 20005097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.
    Monovich LG; Tommasi RA; Fujimoto RA; Blancuzzi V; Clark K; Cornell WD; Doti R; Doughty J; Fang J; Farley D; Fitt J; Ganu V; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Parker DT; Melton R; O'Byrne E; Pastor G; Pellas T; Quadros E; Reel N; Roland DM; Sakane Y; Singh H; Skiles J; Somers J; Toscano K; Wigg A; Zhou S; Zhu L; Shieh WC; Xue S; McQuire LW
    J Med Chem; 2009 Jun; 52(11):3523-38. PubMed ID: 19422229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
    Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
    Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.
    Taylor SJ; Abeywardane A; Liang S; Muegge I; Padyana AK; Xiong Z; Hill-Drzewi M; Farmer B; Li X; Collins B; Li JX; Heim-Riether A; Proudfoot J; Zhang Q; Goldberg D; Zuvela-Jelaska L; Zaher H; Li J; Farrow NA
    J Med Chem; 2011 Dec; 54(23):8174-87. PubMed ID: 22017539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
    Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A
    J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis.
    Kalva S; Saranyah K; Suganya PR; Nisha M; Saleena LM
    J Mol Graph Model; 2013 Jul; 44():297-310. PubMed ID: 23938376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of potent and selective MMP-13 inhibitors.
    Wu J; Rush TS; Hotchandani R; Du X; Geck M; Collins E; Xu ZB; Skotnicki J; Levin JI; Lovering FE
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4105-9. PubMed ID: 16005220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
    Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic characterization of 4,4'-biphenylsulfonamides as selective non-zinc binding MMP inhibitors.
    Santamaria S; Nuti E; Cercignani G; La Regina G; Silvestri R; Supuran CT; Rossello A
    J Enzyme Inhib Med Chem; 2015 Dec; 30(6):947-54. PubMed ID: 25694065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydantoin based inhibitors of MMP13--discovery of AZD6605.
    De Savi C; Waterson D; Pape A; Lamont S; Hadley E; Mills M; Page KM; Bowyer J; Maciewicz RA
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4705-12. PubMed ID: 23810497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for the highly selective inhibition of MMP-13.
    Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
    Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Hu Y; Xiang JS; DiGrandi MJ; Du X; Ipek M; Laakso LM; Li J; Li W; Rush TS; Schmid J; Skotnicki JS; Tam S; Thomason JR; Wang Q; Levin JI
    Bioorg Med Chem; 2005 Dec; 13(24):6629-44. PubMed ID: 16216515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.
    Shi ZH; Li NG; Shi QP; Tang H; Tang YP; Li W; Yin L; Yang JP; Duan JA
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1206-11. PubMed ID: 23375794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.